Skip to content

Search

FBXO11, a regulator of the TGFΒ pathway, is associated with severe otitis media in Western Australian children

Otitis media (OM) is a common childhood disease characterised by middle ear inflammation following infection

Predominance of nontypeable haemophilus influenzae in children with otitis media

In Australia the 7-valent pneumococcal conjugate vaccine (PCV7) is administered at 2, 4 and 6 months of age, with no booster dose.

Crowding and other strong predictors of upper respiratory tract carriage of otitis media-related bacteria

Streptococcus pneumoniae, Moraxella catarrhalis, and nontypeable Haemophilus influenzae is associated with otitis media

Does Child Care in the First Year of Life Pose a Risk for Concurrent and Future Ear Infections?

The longitudinal analyses found no evidence of increased (or decreased) long-term risk of ear infections in subsequent waves associated with attending a child care centre

Australian Aboriginal children have higher hospitalization rates for otitis media but lower surgical procedures than non-Aboriginal children

Aboriginal children and children from lower socio-economic backgrounds were over-represented with OM-related hospitalizations but had fewer TTIs

Topical versus systemic antibiotics for chronic suppurative otitis media

To assess the relative effectiveness of topical versus systemic antibiotics for people with chronic suppurative otitis media

Aural toilet (ear cleaning) for chronic suppurative otitis media

To assess the effects of aural toilet procedures for people with chronic suppurative otitis media

Australian Aboriginal children with otitis media have reduced antibody titers to specific nontypeable Haemophilus influenzae vaccine antigens

decreased serum IgG responses to NTHi outer membrane proteins may contribute to the development of chronic and severe OM in Australian Aboriginal children

Nasal spray to prevent ear infections closer to fruition thanks to major grant

A nasal spray that could potentially prevent childhood ear infections and reduce antibiotic use is a step closer to clinical trials thanks to a $500,000 CUREator grant.